NCT05225259: Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK, RET
Breast Cancer Tissue: 
Recruitment Status: Available

Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult))
Location of Metastases: 
Additional Notes: Patients must be medically suitable for treatment with LOXO-260, but not eligible or able to participate in an ongoing LOXO-260 clinical trial

Comments are closed.

Up ↑